T1	intervention 20 34	pentoxifylline
T2	intervention 39 48	vitamin E
T3	control 52 70	standard follow-up
T4	condition 107 122	breast fibrosis
T5	No-of-participants 386 397	Fifty-three
T6	eligibility 398 443	breast cancer patients with localized disease
T7	intervention-participants 585 587	26
T8	control-participants 615 617	27
T9	outcome-Measure 620 662	Tissue compliance meter (TCM) measurements
T10	duration 1039 1046	2 years
T11	outcome-Measure 1051 1067	local recurrence
T12	outcome-Measure 1069 1090	disease-free survival
T13	outcome-Measure 1096 1112	overall survival
T14	outcome 1118 1153	mean difference in TCM measurements
T16	intervention-value 1335 1339	100%
T17	control-value 1349 1354	90.6%
T18	outcome 1380 1401	disease-free survival
T19	intervention-value 1403 1408	96.2%
T20	control-value 1418 1423	86.8%
T15	outcome 1317 1333	Overall survival
